Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFP-11207 in Advanced Solid Tumors
NCT02171221Phase 1Completed
- Sponsor
- Delta-Fly Pharma, Inc.
- Start
- Jun 2014
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DFP-11207 in solid tumor, sponsored by Delta-Fly Pharma, Inc. Primary endpoints: Maximum Tolerated Dose at 30 days and Pharmacokinetic Profiles under Fed and Fasted Conditions. Started Jun 2014; status: completed.
02
Drugs
DFP-11207
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02171221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171221.